ClinicalTrials.gg
Active, not recruitingNCT07037277Updated Jun 29, 2026

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

A Phase 3 interventional study of Bemnifosbuvir-Ruzasvir and Sofosbuvir-Velpatasvir in HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic and Hepatitis C Virus Infection, sponsored by Atea Pharmaceuticals, Inc.. Active, not recruiting at 107 sites in 17 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Hepatitis C, Chronic with a site in India — none open to participants now, 1 under way, 1 of them phase 3. Hepatitis C, Chronic · India.

Planned enrollment
4th of 16
880 · median 400
Started
2025
the only one that year
Phase 3
7 of 18
none open now
Registered
18th of 18
by date
Lead sponsor
2 of 18
Atea Pharmaceuticals, Inc.

Among the 18 studies in Hepatitis C, Chronic with a site in India, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 3, and was the 18th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 18 studies in Hepatitis C, Chronic with a site in India is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Hepatitis C, Chronic with a site in India as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

03

Conditions studied

  • HEPATITIS C VIRUS CHRONIC INFECTION
  • Hepatitis C, Chronic
  • Hepatitis C Virus Infection
  • Hepatitis C
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Use of adequate for females of
  • Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for )
  • Documented medical history compatible with chronic HCV
  • Either no liver cirrhosis or with compensated liver cirrhosis
  • If -1-positive, must meet the following 2 criteria:

    1. Antiretroviral (ARV) regimen for >8 weeks prior to screening visit, with >200 cells/mm3 and plasma HIV-1 RNA \<LLOQ
    2. Suitable ARV treatment and not taking any medications

Key Exclusion Criteria:

  • Pregnant or breastfeeding
  • Co-infected with virus
  • Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator
  • Prior exposure to any HCV DAA
  • Requirement of any prohibited medications
  • Use of other drugs within 30 days of dosing
  • History or signs of decompensated liver disease (decompensated cirrhosis)
  • History of hepatocellular carcinoma (HCC)
  • Any other medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
880 participants (estimated)

Study arms

  • Experimental
    Bemnifosbuvir - Ruzasvir (BEM/RZR)

    Drug: Bemnifosbuvir-Ruzasvir

  • Active comparator
    Sofosbuvir-Velpatasvir (SOF/VEL)

    Drug: Sofosbuvir-Velpatasvir

Interventions

  • DrugBemnifosbuvir-Ruzasvir

    BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)

    Also known as: (BEM/RZR)

  • DrugSofosbuvir-Velpatasvir

    SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks

    Also known as: (SOF/VEL)

06

What researchers measure

Primary outcomes

  1. Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24

    Time frame: Day 1 through Week 24

Secondary outcomes

  1. Proportion of subjects achieving HCV RNA < LLOQ 12 weeks after the last dose of study drugs

    Time frame: Day 1 through 12 weeks after the end of treatment

  2. Proportion of subjects experiencing virologic failure as measured by HCV RNA RT-qPCR

    Time frame: Day 1 through Week 24

07

Study locations

107 sites
  • Atea Study Site
    Cairo, 11796, Egypt
  • Atea Study Site
    Nice, Alpes Maritimes 06202, France
  • Atea Study Site
    Strasbourg, Bas Rhin 67091, France
  • Atea Study Site
    Clichy, Hauts De Seine 92110, France
  • Atea Study Site
    Montpellier, Herault 34295, France
  • Atea Study Site
    Clermont-Ferrand, Puy De Dome 63003, France
  • Atea Study Site
    Créteil, Val De Marne 94010, France
  • Atea Study Site
    Frankfurt am Main, Hesse 60590, Germany
  • Atea Study Site
    Leipzig, Saxony 04103, Germany
  • Atea Study Site
    Hamburg, 20246, Germany
  • Atea Study Site
    Alexandroupoli, 68100, Greece
  • Atea Study Site
    Athens, 10676, Greece
  • Atea Study Site
    Athens, 11527, Greece
  • Atea Study Site
    Heraklion, 71110, Greece
  • Atea Study Site
    Rhodes, 85100, Greece
  • Atea Study Site
    Hyderabad, Andhra Pradesh 500082, India
  • Atea Study Site
    Patna, Bihar 800014, India
  • Atea Study Site
    Rajkot, Gujarat 360005, India
  • Atea Study Site
    Surat, Gujarat 395002, India
  • Atea Study Site
    Shimla, Himachal Pradesh 171006, India
  • Atea Study Site
    Belagavi, Karnataka 590010, India
  • Atea Study Site
    Kochi, Kerala 682041, India
  • Atea Study Site
    Mumbai, Maharashtra 400008, India
  • Atea Study Site
    Mumbai, Maharashtra 400012, India
  • Atea Study Site
    Nagpur, Maharashtra 440010, India
  • Atea Study Site
    Pune, Maharashtra 411004, India
  • Atea Study Site
    Pune, Maharashtra 411023, India
  • Atea Study Site
    Chandigarh, Punjab 151001, India
  • Atea Study Site
    Ludhiana, Punjab 141001, India
  • Atea Study Site
    Agra, Uttar Pradesh 282002, India
  • Atea Study Site
    Kanpur, Uttar Pradesh 208002, India
  • Atea Study Site
    Lucknow, Uttar Pradesh 226010, India
  • Atea Study Site
    Varanasi, Uttar Pradesh 221005, India
  • Atea Study Site
    Kolkata, West Bengal 700020, India
  • Atea Study Site
    Kota Bharu, Kelantan 15586, Malaysia
  • Atea Study Site
    Kota Bharu, Kelantan 16150, Malaysia
  • Atea Study Site
    Ampang, Kuala Lumpur 68000, Malaysia
  • Atea Study Site
    Kuantan, Pahang 25100, Malaysia
  • Atea Study Site
    Kota Kinabalu, Sabah 88586, Malaysia
  • Atea Study Site
    Kuala Lumpur, 50586, Malaysia
  • Atea Clinical Study Site
    Chisinau, 2025, Moldova
  • Atea Study Site
    Islamabad, 44000, Pakistan
  • Atea Study Site
    Islamabad, 45600, Pakistan
  • Atea Study Site
    Karachi, 74800, Pakistan
  • Atea Study Site
    Karachi, 75190, Pakistan
  • Atea Study Site
    Karachi, 75300, Pakistan
  • Atea Study Site
    Karachi, 75600, Pakistan
  • Atea Study Site
    Lahore, 53100, Pakistan
  • Atea Study Site
    Lahore, 54700, Pakistan
  • Atea Study Site
    Lahore, 54800, Pakistan
  • Atea Study Site
    Peshawar, 25000, Pakistan
  • Atea Study Site
    Rawalpindi, 0000, Pakistan
  • Atea Study Site
    Krakow, 30-901, Poland
  • Atea Study Site
    Kłodzko, 57-300, Poland
  • Atea Study Site
    Lublin, 20-582, Poland
  • Atea Study Site
    Mysłowice, 41-400, Poland
  • Atea Study Site
    Warsaw, 00-124, Poland
  • Atea Study Site
    Wroclaw, 51-162, Poland
  • Atea Study Site
    Bucharest, 020125, Romania
  • Atea Study Site
    Bucharest, 021105, Romania
  • Atea Study Site
    Bucharest, 022328, Romania
  • Atea Study Site
    Bucharest, 030303, Romania
  • Atea Study Site
    Constanța, 900709, Romania
  • Atea Study Site
    Craiova, 200642, Romania
  • Atea Study Site
    Galati, 800179, Romania
  • Atea Study Site
    Iași, 700503, Romania
  • Atea Study Site
    Sibiu, 550245, Romania
  • Atea Study Site
    Suceava, 720201, Romania
  • Atea Study Site
    Port Elizabeth, Eastern Cape 6001, South Africa
  • Atea Study Site
    Bloemfontein, Free State 9301, South Africa
  • Atea Study Site
    Johannesburg, Gauteng 1827, South Africa
  • Atea Study Site
    Johannesburg, Gauteng 2092, South Africa
  • Atea Study Site
    Johannesburg, Gauteng 2193, South Africa
  • Atea Study Site
    Pretoria, Gauteng 0152, South Africa
  • Atea Study Site
    Brits, North West 0250, South Africa
  • Atea Study Site
    Somerset West, Western Cape 7130, South Africa
  • Atea Study Site
    Seoul, Gyeonggi-do 120-752, South Korea
  • Atea Study Site
    Yangsan, Gyeongsangnam-do 626-770, South Korea
  • Atea Study Site
    Busan, 47392, South Korea
  • Atea Study Site
    Busan, 49241, South Korea
  • Atea Study Site
    Seoul, 05505, South Korea
  • Atea Study Site
    Santander, Cantabria 39008, Spain
  • Atea Study Site
    Málaga, Malaga 29010, Spain
  • Atea Study Site
    Vigo, Pontevedra 36211, Spain
  • Atea Study Site
    Barcelona, 08035, Spain
  • Atea Study Site
    Pathum Wan, Bangkok 10330, Thailand
  • Atea Study Site
    Ratchathewi, Bangkok 10400, Thailand
  • Atea Study Site
    Mueang Nonthaburi, Changwat Khon Kaen 40002, Thailand
  • Atea Study Site
    Hat Yai, Changwat Songkhla 90110, Thailand
  • Atea Study Site
    Mueang Nonthaburi, Chiang Mai 50200, Thailand
  • Atea Study Site
    Bangkok, 10330, Thailand
  • Atea Study Site
    Adana, 01790, Turkey (Türkiye)
  • Atea Study Site
    Ankara, 06100, Turkey (Türkiye)
  • Atea Study Site
    Ankara, 06800, Turkey (Türkiye)
  • Atea Study Site
    Bursa, 16310, Turkey (Türkiye)
  • Atea Study Site
    Denizli, 20070, Turkey (Türkiye)
  • Atea Study Site
    Diyarbakır, 2128, Turkey (Türkiye)
  • Atea Study Site
    Istanbul, 34785, Turkey (Türkiye)
  • Atea Study Site
    Kayseri, 38080, Turkey (Türkiye)
  • Atea Study Site
    Samsun, 55270, Turkey (Türkiye)

Showing the first 100 of 107 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 18 months is above that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 25, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07037277
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Jun 2, 2025
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion